CA2647743A1 - Detection of steroid receptors on circulating carcinoma cells and treatment - Google Patents

Detection of steroid receptors on circulating carcinoma cells and treatment Download PDF

Info

Publication number
CA2647743A1
CA2647743A1 CA002647743A CA2647743A CA2647743A1 CA 2647743 A1 CA2647743 A1 CA 2647743A1 CA 002647743 A CA002647743 A CA 002647743A CA 2647743 A CA2647743 A CA 2647743A CA 2647743 A1 CA2647743 A1 CA 2647743A1
Authority
CA
Canada
Prior art keywords
receptor
cells
steroid receptor
carcinoma cells
immunoassay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002647743A
Other languages
English (en)
French (fr)
Inventor
Ming Lu
Robert M. Lorence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2647743A1 publication Critical patent/CA2647743A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002647743A 2006-04-18 2007-04-18 Detection of steroid receptors on circulating carcinoma cells and treatment Abandoned CA2647743A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74501206P 2006-04-18 2006-04-18
US60/745,012 2006-04-18
PCT/US2007/066849 WO2007121459A2 (en) 2006-04-18 2007-04-18 Detection of steroid receptors on circulating carcinoma cells and treatment

Publications (1)

Publication Number Publication Date
CA2647743A1 true CA2647743A1 (en) 2007-10-25

Family

ID=38610453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002647743A Abandoned CA2647743A1 (en) 2006-04-18 2007-04-18 Detection of steroid receptors on circulating carcinoma cells and treatment

Country Status (6)

Country Link
US (1) US20090291920A1 (https=)
EP (1) EP2008107A4 (https=)
JP (1) JP5078100B2 (https=)
CA (1) CA2647743A1 (https=)
MX (1) MX2008013331A (https=)
WO (1) WO2007121459A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582713A1 (en) * 2004-10-06 2006-04-20 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
CA2684265A1 (en) * 2007-04-19 2008-10-30 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
US20110144198A1 (en) 2008-05-16 2011-06-16 Atlas Antibodies Ab Breast cancer prognostics
EP2591363B1 (en) * 2010-07-07 2017-09-20 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
TWI577389B (zh) * 2010-10-14 2017-04-11 維里德克斯有限責任公司 使用多專一性捕捉及雞尾酒檢測試劑檢測胰臟病患之循環腫瘤細胞的方法及套組
US20120252038A1 (en) * 2011-04-01 2012-10-04 Chianese David A Steroid receptor assays
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US20150233932A1 (en) * 2013-02-19 2015-08-20 Ching-Ping Tseng Methods, Systems, and Compositions for Enrichment of Rare Cells
IT201800004137A1 (it) * 2018-03-30 2019-09-30 Domenico Marina Di Metodo di screening in vitro per diagnosi precoce dei tumori del cavo orale e relativo kit, basato in particolare su saggio elisa
EP3906412A1 (en) * 2019-01-03 2021-11-10 Meso Scale Technologies, LLC Compositions and methods for carrying out assay measurements

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
BR0207290A (pt) * 2001-02-16 2005-06-07 Immunivest Corp Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética
EP1597353B1 (en) * 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
JP2006525030A (ja) * 2003-05-07 2006-11-09 セダーズ−シナイ メディカル センター 細胞内エストラジオール結合タンパク質、このタンパク質をコードするポリヌクレオチドおよびこのタンパク質を過剰発現する細胞
CA2582713A1 (en) * 2004-10-06 2006-04-20 Wellstat Biologics Corporation Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US20100105145A1 (en) * 2005-07-01 2010-04-29 Dako Denmark A/S Method of simultaneously visualizing multiple biological targets
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing

Also Published As

Publication number Publication date
US20090291920A1 (en) 2009-11-26
EP2008107A2 (en) 2008-12-31
WO2007121459A2 (en) 2007-10-25
EP2008107A4 (en) 2009-12-23
JP5078100B2 (ja) 2012-11-21
MX2008013331A (es) 2008-11-10
WO2007121459A3 (en) 2009-04-09
JP2009538415A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
US20090291920A1 (en) Detection of steroid receptors on circulating carcinoma cells and treatment
US20110070598A1 (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
JP5025724B2 (ja) 循環腫瘍性細胞からのタンパク質の検出
CA2684265A1 (en) Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
JP2010525326A5 (https=)
US9625461B2 (en) Method of detecting cancer using delta-catenin
WO2005098046A2 (en) Methods for the determination of cell specific biomarkers
US8557531B2 (en) Detection of circulating endothelial cells
JPWO2018131192A1 (ja) 被検者が膵臓癌に罹患している可能性を試験する方法
US9746472B2 (en) Methods and kits for the detection of cancer infiltration of the central nervous system
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
HK1103439B (en) Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
WO2000063231A1 (en) Lymphocyte platelet binding factor as a serum marker for cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140422